Regeneron's 107% Volume Surge Propels It to 133rd in U.S. Trading Amid 3.32% Price Drop

On October 8, 2025, Regeneron Pharmaceuticals (REGN) saw a trading volume of $0.79 billion, marking a 107.2% increase from the previous day’s volume. The stock closed down 3.32%, ranking 133rd in trading activity among U.S. equities.

Recent market activity for Regeneron reflects heightened investor scrutiny amid evolving dynamics in biopharmaceutical sector positioning. The surge in volume suggests intensified short-term positioning or hedging activity, though the price decline indicates potential profit-taking or strategic rebalancing by institutional participants. The stock’s performance remains closely tied to its pipeline developments and broader sector trends.

To conduct a precise back-test of the strategy, the following parameters require clarification: 1. **Universe**: Should the pool include all U.S. common stocks listed on NYSE/Nasdaq/Amex, or exclude ADRs/ETFs? 2. **Ranking/Execution Convention**: Will positions be ranked based on prior-day volume and executed at the next day’s open, or will same-day closing prices determine execution? 3. **Weighting & Capital Allocation**: Should the 500 selected names be equally weighted daily, or will a fixed notional capital allocation (e.g., 100%) be applied consistently? 4. **Costs & Slippage**: Should transaction commissions and bid-ask spreads be factored in, or will a “clean” strategy analysis assume zero costs? 5. **Benchmark**: For comparative analysis, should performance be measured against the S&P 500, Russell 3000, or remain unbenchmarked? Once these parameters are confirmed, a daily trade signal list will be generated, and the back-test will be executed from January 3, 2022, to the present.